The prognosis of pancreatic cancer is extremely poor and early diagnosis is difficult. At the time of diagnosis, local vascular involvement, nodal and distant metastases are frequently present.
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2004 ASCO Annual Meeting. This abstract does not include a full text component.
AZoSensors on MSN
This fluorescent membrane spots pancreatic cancer marker with a simple color change
Molecularly imprinted membranes for a cost-effective solution for detecting CA 19-9, rapid, instrument-free pancreatic cancer ...
A new research paper was published in Oncotarget's Volume 15 on June 13, 2024, entitled, "Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management ...
“[...] these inexpensive, widely available tests with rapid turnaround times and relatively short half-lives (CEA, CA-125, and CA19-9) are perfectly situated to ...
Second interim analysis of the Global Investigation of Therapeutic Decisions in Unresectable HCC (uHCC) and of Its Treatment with Sorafenib (GIDEON): Differences in AE reporting across physician ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback